|
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.〔(Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab ) ''American Medical Association''.〕〔(International Nonproprietary Names for Pharmaceutical Substances (INN) ), ''World Health Organization''.〕 A phase I clinical trial has been conducted in 2006/07. Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. 〔http://www.scarletroadstudy.com/en-CA/index.aspx〕 One clinical study was stopped on December 19, 2014 after disappointing results.〔http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045〕 As of late 2014, Phase III clinical trials are ongoing. == References == 〔 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Gantenerumab」の詳細全文を読む スポンサード リンク
|